Nephrology (Carlton, Vic.)最新文献_第10页

Urinary tubular biomarkers as potential early predictors of renal allograft rejection. 尿小管生物标志物作为肾移植排斥反应的潜在早期预测因子。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2012-01-01 DOI: 10.1111/j.1440-1797.2011.01536.x

Yi-Tian Ting, P Toby Coates, Robert J Walker, Alexander D McLellan

{"title":"Urinary tubular biomarkers as potential early predictors of renal allograft rejection.","authors":"Yi-Tian Ting, P Toby Coates, Robert J Walker, Alexander D McLellan","doi":"10.1111/j.1440-1797.2011.01536.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2011.01536.x","url":null,"abstract":"Confirmation of kidney transplant rejection still requires a histological diagnosis on renal allograft biopsy. Research continues for new non-invasive means for early diagnosis and treatment of kidney allograft rejection. Examination of the urine in renal transplant recipients provides a logical and readily accessible non-invasive window on allograft function, reflecting the function of the kidney in its transplanted environment. Renal tubular epithelial cells (TEC) respond dynamically to the surrounding microenvironment and play an important role in allograft survival. Proteins released from TEC into the urine potentially serve as biomarkers for the early diagnosis of graft dysfunction and rejection. Activated proximal TEC express human leucocyte antigens and co-stimulatory molecules, transiently transforming into non-professional antigen-presenting cells that augment renal allograft rejection. Chemokines and chemoattractants expressed on proximal tubules may also facilitate the migration of alloreactive lymphocytes to local site of injury and stimulate cytokine release from infiltrating lymphocytes. Proximal TEC are also potential targets for circulating alloreactive antibodies and complement leading to cell damage. Changes in cell state during development, regeneration or immune response require a rapid modulation of both surface protein expression and secretion, altering the repertoire of proteins secreted or expressed at the TEC plasma membrane. Due to the proximity of TEC to the tubular lumen, these proteins are passed into the urine. In this regard, TEC possess a unique anatomic location within the transplanted organ and are therefore ideal indicators of graft function. Hence, measurement of the changes of TEC-derived molecules in the urine, in response to different challenges or modification, may predict graft outcome.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"11-6"},"PeriodicalIF":2.5,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2011.01536.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40126815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. KHA-CARI指南:生化和血液学指标:使用促红细胞生成素药物患者的血红蛋白浓度。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2012-01-01 DOI: 10.1111/j.1440-1797.2011.01535.x

Lawrence P McMahon, Robert MacGinley

引用次数: 15

Is vitamin B(6) deficiency an under-recognized risk in patients receiving haemodialysis? A systematic review: 2000-2010. 在接受血液透析的患者中，维生素B(6)缺乏是一种未被认识到的风险吗？系统回顾：2000-2010。

Nephrology (Carlton, Vic.) Pub Date : 2011-09-01 DOI: 10.1111/j.1440-1797.2011.01479.x

Melissa Corken, Judi Porter

{"title":"Is vitamin B(6) deficiency an under-recognized risk in patients receiving haemodialysis? A systematic review: 2000-2010.","authors":"Melissa Corken, Judi Porter","doi":"10.1111/j.1440-1797.2011.01479.x","DOIUrl":"10.1111/j.1440-1797.2011.01479.x","url":null,"abstract":"Vitamin B6 is a water-soluble vitamin, important for the normal functioning of multiple organ systems. In patients receiving haemodialysis, vitamin B6 deficiency has been reported. The impact of ongoing advances in renal medicine on vitamin B6 status has not been evaluated. The aims of this review were (i) to determine the current level of vitamin B(6) deficiency in the haemodialysis population; (ii) to determine the effect of current haemodialysis prescriptions on vitamin B(6) levels; and (iii) to consider the impact of recent medical advances in haemodialysis on vitamin B(6) levels. Electronic databases were used to locate studies with biochemical measures of vitamin B6 between the years 2000 and 2010. Inclusion exclusion criteria were applied by two independent reviewers. Of 316 articles identified, 53 were selected for detailed review. Appropriate vitamin B6 measures and information were extracted. Eleven final studies were included. Vitamin B6 deficiency was shown to be between 24% and 56%. Dialysis reduced plasma levels by 28-48% depending on the dialyser used. Advances in renal medicine including the use of erythropoietin stimulating agents and ion exchange phosphate binding resins were shown to negatively affect vitamin B6 status. Current recommendations for supplementation range from 10-50 mg. These figures are based on older studies often with small numbers of patients. Suboptimal vitamin B6 status is common in the haemodialysis population. Advances in renal medicine and engineering of dialysis membranes may contribute to increased levels of deficiency.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"619-25"},"PeriodicalIF":0.0,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40106584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term outcomes of kidney allografts obtained by transplant tourism: observations from a single center in Korea. 移植旅游获得的同种异体肾脏移植的长期结果:来自韩国单一中心的观察。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2011-09-01 DOI: 10.1111/j.1440-1797.2011.01480.x

Ran-Hui Cha, Yong Chul Kim, Yoon Jung Oh, Jeong Hwan Lee, Eun Young Seong, Dong Ki Kim, Suhnggwon Kim, Yon Su Kim

{"title":"Long-term outcomes of kidney allografts obtained by transplant tourism: observations from a single center in Korea.","authors":"Ran-Hui Cha, Yong Chul Kim, Yoon Jung Oh, Jeong Hwan Lee, Eun Young Seong, Dong Ki Kim, Suhnggwon Kim, Yon Su Kim","doi":"10.1111/j.1440-1797.2011.01480.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2011.01480.x","url":null,"abstract":"Aim: Organ shortages lead end stage renal disease patients to seek overseas kidney transplantations (OTs), but the long-term outcomes of OTs have not been evaluated extensively.Methods: Patients who received OT and were followed at Seoul National University Hospital (SNUH) from 2000 to 2009 (n = 87) were compared with patients who received kidneys from local donors (LTs) and were followed at SNUH (n = 577). Furthermore, we matched OT patients and LT patients via a propensity score using operation date, age, renal replacement therapy duration, and donor sources (n = 87 vs 87).Results: The recipient age was older in the OT group (48 vs 41 years), and donor age was younger in the OT group (29 vs 39 years). The estimated glomerular filtration rates (eGFR) of functioning grafts between the groups were not different throughout the follow-up period. Biopsy-proven acute rejection, infectious disease, and hospitalization were more frequent in the OT group (27/87 vs 141/577, log-rank P < 0.001; 39/87 vs 28/577, log-rank P < 0.001; 66/87 vs 99/577, log-rank P < 0.001). The graft survival rate was lower in the OT group (82/87 vs 542/577, log-rank P = 0.003). Patient survival rate, however, was similar between the groups. After propensity score matching, the donor age was still younger in the OT group (29 vs 38 years). The risks of biopsy-proven acute rejection, infectious disease, and hospitalization were still higher in the OT group (27/87 vs 36/87, log-rank P = 0.04; 39/87 vs 3/87, log-rank P < 0.001; 66/87 vs 19/87, log-rank P < 0.001).Conclusion: Overseas kidney transplantation connotes risk factors that may negatively affect the long-term graft outcome.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"672-9"},"PeriodicalIF":2.5,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2011.01480.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40105925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. 严格的血糖控制可延长终末期肾病糖尿病患者血液透析的生存期。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01273.x

Kenji Shima, Machiko Komatsu, Kazuhiko Kawahara, Jun Minaguchi, Shu Kawashima

{"title":"Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis.","authors":"Kenji Shima, Machiko Komatsu, Kazuhiko Kawahara, Jun Minaguchi, Shu Kawashima","doi":"10.1111/j.1440-1797.2010.01273.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01273.x","url":null,"abstract":"Aim: No suitable index or optimal target for diabetic control has been established for diabetic patients with end-stage renal disease (ESRD) undergoing haemodialysis. To address these issues, the single-centre observational study was conducted.Methods: Two hundred and forty-five diabetic ESRD patients (23.3% female; age at initiation of haemodialysis 61.7 ± 10.7 years) at start of haemodialysis between 1 January 1995 and 31 December 2004 were enrolled. Subjects were grouped according to glycaemic control level throughout the observational period as follows: mean postprandial plasma glucose (PPG) <8.9 mmol/L, 8.9 mmol/L ≤ PPG < 10.0 mmol/L, 10.0 mmol/L ≤ PPG < 11.1 mmol/L, 11.1 mmol/L ≤ PPG < 12.2 mmol/L and PPG ≥ 12.2 mmol/L; and HbA1c < 6.0%, 6.0-6.4%, 6.5-6.9% and ≥ 7.0%. Survival was then followed until 31 December 2005.Results: Cumulative survival of groups of 10.0 mmol/L ≤ PPG < 11.1 mmol/L, 11.1 ≤ PPG < 12.2 and PPG ≥ 12.2 mmol/L was significantly lower than that for PPG < 8.9 mmol/L as determined by Kaplan-Meier estimation (P = 0.016, 0.009 and 0.031, respectively; log-rank test). In both uni- and multivariate Cox proportional hazard models, mortality hazard ratios were significantly higher for PPG ≥ 10.0 mmol/L than for PPG < 8.9 mmol/L (P = 0.002-0.021). Kaplan-Meier survival curves grouped by HbA1c levels showed no correlation between HbA1c and survival during the observational period. No significant difference in mortality hazard ratios was seen for any HbA1c groups evaluated by Cox proportional hazard model.Conclusion: Intensive management of diabetic control at a stringent mean on-study PPG < 10.0 mmol/L will improve the life expectancy in diabetic dialysis patients. However, no range of HbA1c values obtained in this study showed any clear difference in clinical outcomes.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"632-8"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01273.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29312815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Clinicopathological features and prognosis of Chinese patients with acute post-streptococcal glomerulonephritis. 中国急性链球菌感染后肾小球肾炎的临床病理特点及预后分析。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01352.x

Chunlei Luo, Dongmei Chen, Zheng Tang, Yan Zhou, Jinquan Wang, Zhihong Liu, Leishi Li

{"title":"Clinicopathological features and prognosis of Chinese patients with acute post-streptococcal glomerulonephritis.","authors":"Chunlei Luo, Dongmei Chen, Zheng Tang, Yan Zhou, Jinquan Wang, Zhihong Liu, Leishi Li","doi":"10.1111/j.1440-1797.2010.01352.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01352.x","url":null,"abstract":"Aim: To investigate clinicopathological and prognostic differences between adults and children with acute post-streptococcal glomerulonephritis (APSGN).Methods: A retrospective case series of 112 patients with APSGN was undertaken. Patients were divided into two groups according to age: adults aged more than 17 years and children aged less than 15 years.Results: The incidence of APSGN, especially in adults, has decreased in the past three decades. Children have had a higher incidence of macroscopic haematuria than adults (58.3% vs 32.7%, P < 0.05). Laboratory test showed that red blood cell count of urine sediment in children was more significant. On light microscopy, adults had more global glomerulosclerosis, tubular basement membrane thickening, tubular atrophy and interstitial fibrosis, while children had more glomerular infiltrating neutrophils and monocytes and cellular casts. Immunofluorescence microscopy showed that classical staining was seen more in children. The short-term prognoses were good in both children and adults. But the recovery rate of proteinuria in children was faster than that in adults.Conclusion: Adults with APSGN had similar clinical features as children except that children had more significant haematuria. On pathology, adults had more outstanding chronic changes by light microscopy and more untypical staining by immunofluorescence.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"625-31"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01352.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29312814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen. 以雷帕霉素抑制剂为基础的方案在哺乳动物靶点下移植物纤维化的进展。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01365.x

Mumtaz Yilmaz, Ahmet Nart, Sait Sen, Funda Tasli, Adam Uslu, Ender Hur, Mehmet Ozkahya, Cuneyt Hoscoskun, Huseyin Toz

{"title":"Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.","authors":"Mumtaz Yilmaz, Ahmet Nart, Sait Sen, Funda Tasli, Adam Uslu, Ender Hur, Mehmet Ozkahya, Cuneyt Hoscoskun, Huseyin Toz","doi":"10.1111/j.1440-1797.2010.01365.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01365.x","url":null,"abstract":"Aim: Nephrotoxic potential of mammalian target of rapamycin inhibitors (mTORi) is different from calcineurin inhibitors (CNI). The aim of this study is to investigate the interstitial fibrosis (ci) and tubular atrophy (ct) progression from the baseline to first year under a mTORi-based, CNI-free regimen.Methods: Thirty-five kidney transplant recipients who had to have adequate baseline and first year protocol biopsy were enrolled. Exclusion criteria were: the replacement of CNI at any time; acute deterioration in allograft functions; and serum creatinine level above 3 mg/dL at 12 months. Banff criteria were used for histopathological classification. Progression was defined as delta ci + ct ≥ 2 (difference between 12th month and baseline).Results: Mean age of patients and donors were 34 ± 11 and 49 ± 10 years. Twelve patients had delayed graft function (DGF). The maintenance regimen consisted of sirolimus (n = 24) and everolimus (n = 11) with mycophenolate mofetil and steroids. Incidence of acute rejection was 25.7%. At baseline, the incidence of nil and mild fibrosis were 80% and 20%, respectively. At 12 months, 17.1% of patients had moderate, 40% had mild and 42.9% had nil fibrosis. Histological progression from baseline to first year was present in 34% of patients. In multivariate analysis the presence of DGF (P = 0.018) and deceased donor type (P = 0.011) were the most important predictors for fibrosis progression.Conclusion: Progression of graft fibrosis may be seen in one-third of patients under a mTORi-based regimen particularly manifested in deceased donor recipients with subsequent DGF.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"653-8"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01365.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29315484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Transhepatic placement of haemodialysis catheter: A solution for vascular access exhaustion. 经肝放置血液透析导管:血管通路衰竭的解决方案。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01279.x

Desmond Yat Hin Yap, Wai Kuen Tso, Ferdinand Siu Kay Chu, Tak Mao Chan, Kar Neng Lai, Sydney Chi Wai Tang

{"title":"Transhepatic placement of haemodialysis catheter: A solution for vascular access exhaustion.","authors":"Desmond Yat Hin Yap, Wai Kuen Tso, Ferdinand Siu Kay Chu, Tak Mao Chan, Kar Neng Lai, Sydney Chi Wai Tang","doi":"10.1111/j.1440-1797.2010.01279.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01279.x","url":null,"abstract":"10–20%. Kidney injury following intoxication with Amanita manifests as acute tubular necrosis. It usually resolves after resolution of liver injury and in exceptional cases may lead to ESKF. There are no experimental models of Amanita-induced acute kidney injury to address its pathophysiology. Contributory factors to renal injury may be pre-existing kidney disease, hypovolaemia and nephrotoxic drugs. No pre-existent kidney disease was identified in our patient and, except for a tacrolimus, she was not receiving other nephrotoxic drugs. However, it is unlikely that only exposure to tacrolimus, although it may be contributory, was predominantly responsible for development and maintenance of prolonged oliguric acute kidney injury with eventual chronic end-stage kidney disease. Similarly, hepatorenal syndrome should have resolved with successful liver transplantation. With a pathohistological finding of only mild acute tubular injury and mild chronic changes, recovery of renal function should be expected. We speculate that Amatoxin alone or in the combination with medications was responsible for irreversible kidney damage. A successful liver transplantation may have unmasked potential of Amanita intoxication to lead to CKD.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"661-2"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01279.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29339179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. 综述:肾脏疾病的血清和尿液生物标志物:病理生理学的观点。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01361.x

Greg H Tesch

{"title":"Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective.","authors":"Greg H Tesch","doi":"10.1111/j.1440-1797.2010.01361.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01361.x","url":null,"abstract":"The use of reliable biomarkers is becoming increasingly important for the improved management of patients with acute and chronic kidney diseases. Recent developments have identified a number of novel biomarkers in serum or urine that can determine the potential risk of kidney damage, distinguish different types of renal injury, predict the progression of disease and have the potential to assess the efficacy of therapeutic intervention. Some of these biomarkers can be used independently while others are more beneficial when used in combination with knowledge of other clinical risk factors. Advances in gene expression analysis, chromatography, mass spectrometry and the development of sensitive enzyme-linked immunosorbent assays have facilitated accurate quantification of many biomarkers. This review primarily focuses on describing new and established biomarkers, which identify and measure the various pathophysiological processes that promote kidney disease. It provides an overview of some of the different classes of renal biomarkers that can be assessed in serum/plasma and urine, including markers of renal function, oxidative stress, structural and cellular injury, immune responses and fibrosis. However, it does not explore the current status of these biomarkers in terms of their clinical validation.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"609-16"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01361.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29312813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 134

Review: The role of microRNAs in kidney disease. 综述:microRNAs在肾脏疾病中的作用。

IF 2.5

Nephrology (Carlton, Vic.) Pub Date : 2010-09-01 DOI: 10.1111/j.1440-1797.2010.01363.x

Jordan Yz Li, Tuck Y Yong, Michael Z Michael, Jonathan M Gleadle

{"title":"Review: The role of microRNAs in kidney disease.","authors":"Jordan Yz Li, Tuck Y Yong, Michael Z Michael, Jonathan M Gleadle","doi":"10.1111/j.1440-1797.2010.01363.x","DOIUrl":"https://doi.org/10.1111/j.1440-1797.2010.01363.x","url":null,"abstract":"MicroRNAs (miRNAs) are short non-coding RNAs that modulate physiological and pathological processes by inhibiting target gene expression via blockade of protein translation or by inducing mRNA degradation. These miRNAs potentially regulate the expression of thousands of proteins. As a result, miRNAs have emerged rapidly as a major new area of biomedical research with relevance to kidney disease. MiRNA expression has been shown to differ between the kidney and other organs as well as between different kidney regions. Furthermore, miRNAs have been found to be functionally important in models of podocyte development, diabetic nephropathy and polycystic kidney disease. Of particular interest, podocyte-specific deletion of Dicer, a key enzyme in the biogenesis of miRNA, results in proteinuria and severe renal impairment in mice. One miRNA (miR-192) can also act as an effector of transforming growth factor-β activity in the high-glucose environment of diabetic nephropathy. Differential expression of miRNAs has been reported in kidney allograft rejection. It is anticipated that future studies involving miRNAs will generate new insights into the complex pathophysiology underlying various kidney diseases, generate diagnostic biomarkers and might be of value as therapeutic targets for progressive kidney diseases. The purpose of this review is to highlight key miRNA developments in kidney diseases and how this might influence the diagnosis and management of patients with kidney disease in the future.","PeriodicalId":520716,"journal":{"name":"Nephrology (Carlton, Vic.)","volume":" ","pages":"599-608"},"PeriodicalIF":2.5,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1440-1797.2010.01363.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29312812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 133